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SUMMARY
In isolated rat white adipocytes, epinephrine (in the presence of
1 0 MM propranolol) increased the uptake of [32P]P into phospha-
high affinity (Kd values of 0.75 ± 0.20 nri for [3H]bunazosin and
1 25 ± 20 M for 1251-HEAT), in a rapid, reversible, and saturable
tidylinositol in a dose-dependent fashion. When the cells were (Bmax, 91 2 fmol/mg of protein) fashion, and with the expected
pretreated with the irreversible antagonist chlorethylclonidine, pharmacological characteristics for a1-adrenoceptors. Binding
this a1-adrenergic effect was markedly diminished. The effect of displacement studies with these ligands indicated a potency
epinephrine was dose-dependently antagonized by selective a- order of prazosin > 5-methylurapidil  WB41 01 . Northern blot
adrenergic antagonists, with the potency order prazosin > 5- analysis using receptor subtype-specific gene probes showed
methylurapidil  WB41 01 . Binding studies using crude mem- that adipocyte mRNA hybridized with the alB-adrenergic probe.
brane preparations were performed with the Iigands [3H]buna-
zosin and 125l-HEAT. Both ligands bound to membrane sites with
All these data suggest that the a1-adrenoceptors of rat white
adipocytes belong to the a16 subtype.
Catecholamines are among the main modulators of adipocyte In the present study, we examined the subtype of s,-adre-
metabolism (1). Three basic types of adrenoceptors are present noceptor present in isolated rat adipocytes, using a metabolic
in these cells, i.e., a,-, a2-, and 3-adrenoceptors (1). The effects response (P1 labeling), radioligand binding techniques, and
of catecholamines on cAMP accumulation are mediated Northern blot analysis.
through regulation of adenylate cyclase activity, which is acti-
vated by $-adrenoceptors and inhibited by ce2-adrenoceptors. Materials and Methods
Activation of cs,-adrenoceptors is associated with phosphoino- l-Epinephrine, dl-propranolol, and prazosin were obtained from
sitide turnover and calcium mobilization (1, 2). Sigma Chemical Co. (St. Louis, MO). Chlorethylclonidine, 5-methylur-
Activation of a,-adrenoceptors in white adipocytes increases apidil, and WB41O1 were obtained from Research Biochemicals Inc.
the uptake of [:t2p]p. into P1 (3-6). This increased P1 labeling
seems to be secondary to the initial breakdown of phosphati-
dylinositol-4,5-bisphosphate to inositol-1,4,5-trisphosphate
and diacylglycerol, by a phosphoinositidase (7). Other ce,-adre-
nergic actions have been observed in adipocytes and include
activation of glycogen phosphorylase (8, 9), inactivation of
(Natick, MA). Collagenase was from Worthington (Freehold, NJ). [2PJ
 (carrier-free) and ‘251-HEAT (2200 Ci/mmol) were from New Eng-
land Nuclear (Boston, MA). [3HjBunazosin (54 Ci/mmol) was gener-
ously provided by Eizai Co., Ltd. (Japan). The s,-adrenoceptor gene
probes were generously provided by Drs. Lomasney, Cotecchia, Caron,
and Leflwwitz (Duke University).
Male Wistar rats (300-350 g), fed ad libitum, were used. Rats were
glycogen synthase (5, 8, 9), and stimulation of 42K efflux (10); sacrificed by decapitation, and the epididymal fat pads were removed.
these actions seem to be due to elevated cytosol [Ca2]. Fat cells were isolated by the method of Rodbell (15). The methodology
Heterogeneity of cr,-adrenoceptors has been demonstrated by
pharmacological and molecular biological techniques. The ex-
istence of two subtypes of a,-adrenoceptors, alA and cs,o, was
initially suggested by pharmacological data (1 1); these receptors
have now been cloned and expressed (12, 13). A new subtype,
the a,(--adrenergic receptor, not previously evidenced by phar-
macological criteria, has also now been cloned and expressed
to study P1 labeling in fat cells has been reported in detail elsewhere
 In brief, adipocytes were incubated in Krebs-Ringer Tris buffer
supplemented with 6% albumin and 10 l1Ci/ml radioactive phosphate,
for 60 mm. Phospholipids were extracted with chloroform/methanol
(2:1), followed by silicic acid adsorption. Separation of phospholipids
was performed using one-dimensional thin layer chromatography. In-
corporation of label was determined directly, by counting silica gel
scrapings of individual phospholipids. The incorporation of label and
(14). the phospholipid composition were identical to those reported previ-
This research was partially supported by grants from DGAPA (IN 201889)
ously (3).
For the binding studies, a crude membrane preparation was obtained
and CONACyT (0310-N9107). from the isolated adipocytes (4). [‘HjBunazosin binding was measured
ABBREVIATIONS: P1, phosphatidylinositol; SSC, sodium chloride/sodium citrate; kb, kilobases; ‘251-HEAT, 2f3-(4-hydroxy-3-’25l-iodo-
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as described by Kobatake et al. (16), with some minor modifications.
In brief, 1 mg of membrane protein was incubated with [H]bunazosin
(0.05-2.5 nM in saturation experiments or 1.25 nM in binding displace-
ment experiments), in 50 mM Tris, 10 mM MgCl2, pH 7.5, for 20 mm
at 25, in a total volume of 0.5 ml. The incubation was terminated by
the addition of 10 ml of ice-cold buffer; the suspension was filtered
through GF/C filters, which were then washed three times with 10 ml
of the same buffer and counted in a scintillation counter with an
efficiency of 40%. Nonspecific binding was evaluated in the presence
of 1 MM prazosin; specific binding usually represented 60% of total
binding at the Kd. Binding of ‘251-HEAT was assayed as described by
Lomasney et a!. (12), with some modifications. Membranes (300 g of
protein) were incubated with ‘251-HEAT (10-300 M in saturation
experiments and 100 pM in binding competition experiments), in 1 ml
of 50 mM Tris, 150 mM NaCI, 5 mM EDTA, 0.2% albumin, pH 7.4, for
60 mm at 25’. The incubation was terminated by the addition of 10 ml
of ice-cold buffer, and the mixture was filtered through GF/C filters,
which were washed three times with 10 ml of the same buffer and
counted in a y counter. Nonspecific binding was determined in the
presence of 1 MM prazosin; specific binding represented 40% of total
binding at the Kd. The K, values were calculated according to the
method of Cheng and Prusoff (17).
Total RNA was extracted with phenol and precipitated with ethanol,
as described (18). To perform the Northern blot analysis, 100 g of
total RNA were subjected to electrophoresis in a 1.5% agarose gel with
17% formaldehyde; electrophoresis and electrotransfer were performed
using standard conditions, and the filters were hybridized under high
stringency conditions (18), with 50% formamide. After hybridization,
the membranes were washed three times with 2x SSC ( 150 mM sodium
chloride, 15 mM sodium citrate, pH 7.4), 0.1% sodium dodecyl sulfate,
for 5 mm at room temperature, twice with 0.1x SSC, 0.1% SDS, at 50
for 30 mm, and twice with 0.lx SSC at room temperature for 5 mm.
Gene-specific probes were labeled by nick translation, to a specific
activity of >iO cpm/j.ag. In all experiments, 1 g of radioactive probe
was used for the hybridization. After the washes, the filters were
autoradiographed for 7-10 days at -70’.
Hybridization probes were as follows: the cs,A-adrenoceptor probe
was the 0.85-kb BamHI fragment (12); the cs,-adrenoceptor probe was
the 0.81-kb EcoRI-BamHI fragment of the hamster a,-adrenoceptor
cDNA (13) (subcloned in SP65 at the EcoRI site); and the a,-adre-
noceptor probe was the 1.02-kb BglII-HindIII fragment (14).
Results
In agreement with our previous results (3, 5, 6), epinephrine
in the presence of 10 MM propranolol stimulated P1 labeling in
a dose-dependent fashion, with an EC of 1 MM (Fig. 1, left).
Pretreatment of the cells with the alkylating antagonist chior-
ethylclonidine (100 MM for 15 mm) markedly diminished the
a,-adrenergic effect, from a 3.5-fold increase in labeling to a
stimulation of only 60-80% over basal (Fig. 1, left); the pre-
treatment with chlorethylclonidine was without effect on P1
labeling by itself (data not shown), and it was receptor specific,
as evidenced by the fact that the stimulation of P1 labeling
induced by 0.1 MM oxytocin was not altered (545 ± 75 and 505
± 40% of basal labeling in control and chlorethylclonidine-
treated cells, respectively; means ± standard errors of three
experiments, in duplicate, in each case).
We next examined the effect of reversible a,-adrenergic-
selective antagonists. The effect of 10 MM epinephrine (in the
presence of 10 iM propranolol) was dose-dependently inhibited
by these antagonists, with the order of potency prazosin > 5-
methylurapidil  WB41O1 (Fig. 2, right); the K values are
presented in Table 1.
In agreement with the data of Kobatake et al. (16), we




Fig. 1. Effect of a,-adrenergic agents on PI labeling in isolated rat
adipocytes. Left, adipocytes were preincubated without (#{149})or with 100
MM chlorethylclonidine (A) for 15 mm, washed, and incubated with 10 M
propranolol and different concentrations of epinephrine. Right, cells were
incubated with 10 M epinephrine (plus 10 MM propranolol) and different
concentrations of prazosin (0), 5-methylurapidil (a), or WB41 01 4.
Results are expressed either as percentage of basal, which was 1934 ±
301 cpm/1 06 cells (left) or as percentage of the stimulation induced by
10 MM epinephnne (right). The means are plotted, and vertical lines
represent the standard error, of five or six experiments, using different
cell preparations.
[H] Bunazosin (nM) -Log [Antagonist] M
Fig. 2. Saturation and displacement of specific [3H]bunazosin binding.
Left, specific binding as a function of radioligand concentration (inset,
Scatchard plot analysis). Right, displacement of [3H]bunazosin specific
binding by the indicated concentrations of prazosin (0), 5-methylurapidil
(ts), or WB41 01 4. Experiments representative of three to five, using
different membrane preparations, are presented.
a rapid, reversible, and stereospecific manner, with the phar-
macological characteristics of , -adrenoceptors (data not
shown). Saturation experiments and their Scatchard analysis
indicated the presence of a single class of sites for this ligand,
with a Kd of 0.75 ± 0.20 nM and a B,,,ax Of 12 ± 3 fmol/mg of
protein (means ± standard errors of three experiments, in
1 2 34 56
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K, values for a1-adrenergic antagonists
























Fig. 3. Saturation and displacement of specific ‘25l-HEAT binding. Left,
specific binding as a function of radioligand concentration (inset, Scat-
chard plot analysis). Right, displacement of 125l-HEAT specific binding by
the indicated concentrations of prazosin (0), 5-methylurapidil (a), or
WB41 01 4. Experiments representative of three to five, using different
membrane preparations, are presented.
triplicate); a representative experiment is presented in Fig. 2
(left). Binding competition experiments showed that the a,-
adrenergic antagonists competed for the [3Hjbunazosmn binding
sites with the order of potency prazosin > 5-methylurapidil 
WB41O1; a representative experiment is presented in Fig. 2
(right), and the K values are given in Table 1.
Binding of ‘21-HEAT to adipocyte membranes was also rapid
and reversible. In saturation experiments, a Kd of 125 ± 20 PM
and a B,nax of 9 ± 2 fmol/mg of protein were determined (means
± standard errors of six experiments, in triplicate); a repre-
sentative experiment is presented in Fig. 3 (left). Agonists
competed for the ‘251-HEAT binding sites with the following K,
values: l-epinephrine, 550 ± 150 nM; l-norepinephrine, 970 ±
250 nM; phenylephrine, 1170 ± 90 nM; and d-epinephrine,
10000 ± 3000 nM (means ± standard errors of three or four
experiments, in triplicate). a,-Adrenergic antagonists competed
for these binding sites with the order of potency prazosin > 5-
methylurapidil  WB41O1; a representative experiment is pre-
sented in Fig. 3 (right), and the K, values are given in Table 1.
Northern blot analysis showed that total adipocyte mRNA
hybridized with the a,0-adrenoceptor probe but not with the
other subtype-selective probes (Fig. 4). In one experiment, a
weak signal was observed using the alA probe; however, the
signal was minor and it was not consistently observed.
Fig. 4. Northern blot of adipocyte mRNA probed with a,-adrenoceptor
subtype-selective probes. Total RNA (100 Mg/lane) was subjected to
electrophoresis and electrotransferred. The filter was cut and the mem-
brane fragments were hybridized with the alA- (lanes 1 and 2), s,-
(lanes 3 and 4), or a,c-selective (lanes 5 and 6) probes. The figure is
representative of five experiments, using different cell preparations.
Discussion
In the present work, we characterized the a,-adrenoceptors
of isolated rat white adipocytes using different methodological
approaches, i.e., a metabolic parameter (P1 labeling), binding
saturation and displacement studies, and Northern blot analy-
sis. These different approaches gave entirely consistent results.
Although admittedly a secondary response, the a,-adrenergic
stimulation of P1 labeling is a large, easy to quantify, reproduc-
ible effect in fat cells, and it has been previously characterized
pharmacologically (3, 6). The initial event, i.e., the accumula-
tion of inositol-1,4,5-trisphosphate, can also be determined, but
usually the adrenergic effect is small, which complicates the
pharmacological characterization (19).’
It has been difficult to detect a,-adrenoceptors in white fat
cells membranes by direct binding techniques. Initial studies
using [:IH]prazosin detected a binding site that did not repre-
sent a,-adrenoceptors (20). Only very recently, Kobatake et al.
(16) succeeded in this task, using [:tH]bunazosin a hydrophilic,
highly selective, cs,-adrenergic blocker (21, 22). In the present
manuscript, we confirmed their findings and used this ligand
to characterize further the subtype of receptor involved. We
detected 50% fewer receptors per milligrams of protein than
did Kobatake et al. (16), which could be due to the strains of
rats used (Wistar in our study, compared with Sprague-Daw-
ley). This required the use of very large amounts of membrane
protein in the binding assays; fortunately, the nonspecific bind-
ing was low. ‘9-HEAT was also used in this study, and it was
found to be a suitable ligand; it has a much higher specific
activity, which allowed us to use less membrane protein in the
binding assays. Unfortunately, the nonspecific binding was also
higher. In spite of these difficulties, we observed good agree-
ment between binding assays and the metabolic data.
Among the adrenergic agents that have been used for the
classification of a,-adrenoceptors, three have been particularly
useful, i.e., chlorethylclonidine (11), WB41O1 (23), and 5-meth-
406 Torres-M#{225}rquezet a!.
ylurapidil (24). Chlorethylclonidine is an irreversible antago-
nist that blocks  and a,- but not a,-adrenoceptors (11-
14). The reversible antagonists 5-methylurapidil and WB41O1
have very high affinity for a,- and a,(.-adrenoceptors and lower
affinity for receptors of the a,, subtype (12-14, 23, 24). The
high sensitivity to chlorethylclonidine of white adipocyte a,-
adrenoceptors rules out the possibility that they belong to the
(I,’ subtype; the relatively low affinities for 5-methylurapidil
and WB41O1 suggest that these adrenoceptors are of the a,0-
subtype. Previously, Morrow and Creese (23) predicted, by
analyzing the phentolamine/prazosin potency ratios of our data
on epinephrine-stimulated P1 labeling, that the adrenoceptors
of fat cells belong to the a,11 subtype. This is consistent with
our present findings. However, we would like to point out that
these a,,,-adrenoceptors have some differences with respect to
receptors in other systems, such as rat hepatocytes. For exam-
ple, methoxamine, which is only weakly active in liver cells at
very high concentrations (25, 26), has good activity in fat cells
(3, 5, 8, 9). Obviously, factors such as the type of guanine
nucleotide-binding protein(s) involved or the intracellular am-
plification of the signal participate in the overall response and
may explain some of the differences observed.
In our studies, the Northern blot analysis showed hybridi-
zation with the a,,1-adrenergic probe. Previously, it was ob-
served that adipose tissue mRNA gave some signal with the alA
probe (12, 25). The discrepancy is probably due to the fact that
adipose tissue contains, besides adipocytes, several other cell
types (vascular, endothelial, etc.). In fact, the presence of some
of these cells could explain why we observed a weak alA signal
in one of the fat cell preparations (i.e., cell contamination).
In summary, using biochemical, pharmacological, and molec-
ular biological approaches, our results indicate that rat white
adipocyte a,-adrenoceptors belong to the  subtype.
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